A real-world retrospective observational study to determine post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients
Latest Information Update: 17 Nov 2021
At a glance
- Drugs Midostaurin (Primary) ; Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 17 Nov 2021 New trial record
- 01 Oct 2021 Results published in the Leukemia and Lymphoma